Apple faces a stunning $634 million jury ruling after a major smartwatch patent battle

A long-running patent dispute finally delivers a massive verdict

After years of legal sparring, Apple has been hit with a jury verdict that sharply raises the stakes in its smartwatch battle with medical tech firm Masimo.

A federal jury in California ruled that Apple’s blood-oxygen-related features in Apple Watch infringed a Masimo patent tied to patient monitoring.

The award of $634 million is one of the most eye-catching outcomes yet in Apple’s growing list of courtroom fights.

How a medical sensor patent ended up at the heart of Apple Watch

At the center of the case is pulse oximetry-style technology used to track blood oxygen levels. Masimo argued that Apple had incorporated elements of its patient monitoring inventions into consumer features, such as Workout mode and heart rate notifications on the Apple Watch.

The jury agreed that these functions effectively used Masimo’s patented approach, treating the watch as a patient monitor even in everyday fitness scenarios.

Apple pushes back and frames the ruling as deeply flawed

Apple has made it very clear that it disagrees with the verdict and plans to appeal. The company notes that Masimo has sued it in multiple courts on more than two dozen patents, with many of those claims subsequently found to be invalid.

Apple also stresses that the patent at issue expired in 2022 and describes it as based on historic monitoring technology, not cutting-edge inventions aimed at modern consumer wearables.

Masimo casts the decision as validation of its innovation story

For Masimo, the verdict is more than just money. The company called the ruling a significant win in its efforts to protect its intellectual property and support ongoing medical innovation.

Masimo has long argued that Apple hired away key employees and leveraged its pulse oximetry expertise to power features on the  Apple Watch.

This ruling gives Masimo a boost in both legal and symbolic momentum in a fight where Apple’s size and brand power often overshadows it.

The smartwatch battle has spilled over into multiple courts and agencies

This jury trial is only one branch of a broader, multi-front conflict. Masimo has pursued Apple over allegations of poaching staff, misuse of trade secrets, and repeated patent infringement.

A previous trade-secret claim ended in a 2023 mistrial, and a countersuit awarded Apple only $250 in damages.

What started as a dispute over sensor technology has evolved into a test case for how far a tech giant can go when blending medical-grade ideas into mainstream consumer devices.

Regulators have already stepped in with an import ban on key models

The fight has reached beyond courtrooms into trade policy. The United States International Trade Commission previously ruled that certain Apple Watches infringed Masimo’s pulse oximetry patents, triggering an import ban on models like the Series 9e and Ultra 2o.

That forced Apple into a rare, evident retreat on a flagship feature. It removed blood-oxygen reading capability in affected models while working on a redesign.

Apple redesigns blood oxygen features

To navigate the import restrictions, Apple reintroduced blood oxygen monitoring using an updated implementation that shifted how data is handled.

The redesigned implementation shifts blood-oxygen data processing to the paired iPhone rather than solely on the watch, according to CBP approval.

United States Customs and Border Protection approved the revised designs for import. Still, Masimoo responded by suing Customs, arguing the agency exceeded its authority by greenlighting Apple’s workaround without proper input.

The updated watches now face fresh scrutiny

Even after Apple’s redesign, the regulatory cloud has not lifted. The trade commission has launched a new proceeding to determine whether the updated Apple Watch models should still be subject to the original import ban.

That means Apple’s workaround is under formal review and could yet be rejected. For a company that depends heavily on predictable product cycles, lingering uncertainty over whether it can ship its top wearables is a severe strategic headache.

The alleged infringement spans millions of devices

The verdict is not just about one feature on a few niche models. Court filings indicate the verdict covers roughly 43 million Apple Watch units sold between 2020 and 2022, including mainstream fitness and health users who rely on heart rate alerts and workout metrics.

That scale helps explain the size of the damages figure and why both sides have invested so heavily in this case and its related battles.

The ruling raises questions about how Apple blends medical and consumer tech

Apple has spent years positioning the watch as a health companion, not merely a notification gadget. However, this case illustrates how quickly the line between wellness and regulated medical technology can become blurred.

By edging closer to clinical-grade monitoring, Apple has exposed itself to patent claims from established medical technology firms.

The verdict may push Apple to be more cautious with future health features or to invest more aggressively in its own proprietary sensor innovations.

Masimo gains leverage while Apple weighs its next legal and product moves

For Masimo, the jury ruling strengthens its negotiating position and public narrative. Apple introduces a mix of financial, legal, and reputational risks.

The company must decide whether to settle, redesign again, or fight through appeals that could take years.

Each path carries consequences for its smartwatch roadmap and for how far it pushes into advanced health monitoring at a time when regulators and competitors are watching closely.

Investors and rivals study what this means for future health wearables

A verdict of this size sends a signal to the entire wearables industry. It suggests that courts and regulators are willing to treat consumer devices as patient monitors when advanced biosensing is involved.

That could embolden other medical technology companies to enforce their patents against big tech firms, especially as smartwatches, rings, and other devices incorporate more clinical-style features.

At the same time, it may prompt tech companies to pursue deeper partnerships rather than parallel development.

Curious how these legal pressures intersect with Apple’s talent pipeline? Learn more about why a key AI search executive just left for Meta here.

Apple’s appeal will shape the next chapter in health technology innovation

The story is far from over. Apple’s appeal could reduce the damages, reshape the legal rationale, or even trigger a settlement that includes licensing, technology sharing, or future collaboration.

Whatever the outcome, this case highlights how central health features have become to Apple’s strategy and how fiercely incumbents will protect their innovations.

It also highlights a broader truth about modern tech growth: every significant advance brings a courtroom test right on its heels.

Curious how Apple is evolving its ecosystem amid these legal battles? Please take a look at its upcoming digital Passports and IDs for iPhone here.

What do you think about Apple facing a lawsuit against patent infringement? Please share your thoughts and drop a comment.

Read More From This Brand:

• The AI stock quietly set to join the $3 trillion club with Apple, Nvidia, and Microsoft
• Apple hit with £1.5B fine after UK App Store defeat
• Apple may ditch iPhone 19 to mark 20 years of iPhone

Don’t forget to follow us for more exclusive content on MSN.

If you liked this story, you’ll LOVE our FREE emails. Join today and be the first to get stories like this one.

This slideshow was made with AI assistance and human editing.